A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

This study is testing a new drug called CLN-978 — given by injection under the skin — in people with rheumatoid arthritis (RA) that hasn't responded to at least two different targeted treatments. CLN-978 is designed to deplete B cells, which are immune cells that drive joint inflammation in RA. **You may be eligible if...** - You have had a confirmed RA diagnosis for at least 12 weeks - Your RA is still active (a disease activity score of 3.2 or higher, with at least one swollen joint) - You have already tried and failed at least 2 different targeted RA therapies (including biologics or targeted synthetic DMARDs), after failing conventional DMARDs - Your blood tests show sufficient levels of immune cells and organ function **You may NOT be eligible if...** - You have another active inflammatory disease (other than secondary Sjögren's or thyroiditis) - You have a serious unstable medical condition unrelated to RA - You have received certain prior treatments that the study team will specify Talk to your doctor to see if this trial is right for you.